By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Current study results on Biotechnology have been published. According to news reporting originating from Philadelphia, Pennsylvania, by NewsRx correspondents, research stated, "Upregulation of CD137 (4-1BB) on recently activated CD8(+) T cells has been used to identify rare viral or tumor antigen-specific T cells from peripheral blood. Here, we evaluated the immunobiology of CD137 in human cancer and the utility of a CD137-positive separation methodology for the identification and enrichment of fresh tumor-reactive tumor-infiltrating lymphocytes (TIL) or tumor-associated lymphocytes (TAL) from ascites for use in adoptive immunotherapy."
Our news editors obtained a quote from the research from the University of Pennsylvania, "TILs from resected ovarian cancer or melanoma were measured for surface CD137 expression directly or after overnight incubation in the presence of tumor cells and homeostatic cytokines. CD137(pos) TILs were sorted and evaluated for antitumor activity in vitro and in vivo. Fresh ovarian TILs and TALs naturally expressed higher levels of CD137 than circulating T cells. An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzymedigested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2. Enriched CD137 pos TILs, but not PD-1 pos or PD-1(neg) CD137(neg) cells, possessed autologous tumor reactivity in vitro and in vivo. In melanoma studies, all MART-1-specific CD8(+) TILs upregulated CD137 expression after incubation with HLA-matched, MART-expressing cancer cells and antigen-specific effector function was restricted to the CD137 pos subset in vitro. CD137 pos TILs also mediated superior antitumor effects in vivo, compared with CD137 neg TILs."
According to the news editors, the research concluded: "Our findings reveal a role for the TNFR-family member CD137 in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of TILs, thus rationalizing its agonistic engagement in vivo and its use in TIL selection for adoptive immunotherapy trials."
For more information on this research see: CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor. Clinical Cancer Research, 2014;20(1):44-55. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - clincancerres.aacrjournals.org/)
The news editors report that additional information may be obtained by contacting Q.R. Ye, University of Pennsylvania, Perelman Sch Med, Abramson Canc Center, Dept. of Pathol & Lab Med, Philadelphia, PA 19104, United States. Additional authors for this research include D.G. Song, M. Poussin, T. Yamamoto, A. Best, C.S. Li, G. Coukos and D.J. Powell (see also Biotechnology).
Keywords for this news article include: Biotechnology, Cancer, Oncology, Immunology, Blood Cells, CD Antigens, Philadelphia, Pennsylvania, CD8 Antigens, United States, Immunotherapy, Differentiation, Immunomodulation, Biological Factors, T-Lymphocyte Antigens, Mononuclear Leukocytes, Hemic and Immune Systems, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC